Skip to content

US · CTNM · BIOTECHNOLOGY

Contineum Therapeutics, Inc. (CTNM) intrinsic value and stock valuation

$8.68as of 2026-11-21 · Mkt cap 565.82M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Contineum Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values CTNM with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CTNM’s statements →

Contineum Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 contineum-tx.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$0.00
20212025
Net income
-$-59.98M
20212025
Free cash flow
-$-55.54M
20212025
Total equity
$261M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$0.00$0.00$50M$0.00$0.00
Operating income-$-68.06M-$-50.89M-$-16.08M-$-22.72M-$-28.65M
Net income-$-59.98M-$-42.26M$22.7M-$-24.25M-$-29M
EPSd-$-2.17M-$-1.63M$904.1K-$-964.98K-$-1.15M
Operating cash flow-$-55.31M-$-32.84M$19.4M-$-20.12M-$-26.27M
Capital expenditure-$-230K-$-510K-$-410K-$-120K-$-170K
Free cash flow-$-55.54M-$-33.36M$18.9M-$-20.24M-$-26.43M
Total assets$276.6M$212.9M$130.4M$50.6M$70.5M
Total debt$8.25M$6.26M$193.2M$5.85M$4.91M
Net debt-$-67.35M-$-15.68M$177.7M$280K$280K
Total equity$261M$198.1M-$-67.94M$39.3M$61.6M
Cash and short-term investments$262.9M$204.8M$125.2M$47.2M$69M
Income statement
20252024202320222021
Revenue$0.00$0.00$50M$0.00$0.00
Cost of revenue$0.00$260K$0.00$0.00$0.00
Gross profit$0.00-$-260K$50M$0.00$0.00
Research and development expenses$51.5M$38.2M$27.6M$16.9M$22.4M
Selling, general and administrative expenses$16.5M$12.5M$6.32M$5.83M$6.29M
Other expenses$0.00$0.00$32.2M$0.00-$-90K
Operating expenses$68.1M$50.6M$66.1M$22.7M$28.7M
Cost and expenses$68.1M$50.9M$66.1M$22.7M$28.7M
Interest income$8.25M$8.9M$4.61M$760K$80K
Interest expense$0.00$0.00$210K$390K$330K
Depreciation and amortization$320K$260K$200K$330K$330K
Ebitda-$-67.74M-$-42M$23.6M-$-23.54M-$-28.34M
Operating income-$-68.06M-$-50.89M-$-16.08M-$-22.72M-$-28.65M
Total other income/expenses, net$8.08M$8.64M$39.3M-$-1.53M-$-350K
Income before tax-$-59.98M-$-42.26M$23.2M-$-24.25M-$-29M
Income tax expense$0.00$0.00$450K$0.00$0.00
Net income-$-59.98M-$-42.26M$22.7M-$-24.25M-$-29M
Weighted average shares outstanding$27.7M$25.9M$25.1M$25.1M$25.1M
Weighted average diluted shares outstanding$27.7M$25.9M$25.1M$25.1M$25.1M
Balance sheet
20252024202320222021
Cash and short-term investments$262.9M$204.8M$125.2M$47.2M$69M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$267.9M$206.4M$127.7M$48.4M$69.8M
Property, plant and equipment, net$8.47M$6.46M$1.4M$2.12M$640K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$8.72M$6.46M$2.68M$2.24M$740K
Total assets$276.6M$212.9M$130.4M$50.6M$70.5M
Accounts payable$1.02M$1.81M$640K$430K$660K
Short-term debt$2.34M$1.45M$460K$5.06M$1.25M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$9.74M$9.97M$5.48M$7.55M$3.67M
Long-term debt$5.91M$4.81M$192.7M$790K$3.66M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$5.91M$4.81M$192.8M$3.82M$5.26M
Capital lease obligations$8.25M$6.26M$570K$1.9M$0.00
Total liabilities$15.7M$14.8M$198.3M$11.4M$8.93M
Common stock$40K$30K$0.00$10K$10K
Retained earnings-$-177.38M-$-117.4M-$-75.14M-$-97.86M-$-73.61M
Accumulated other comprehensive income (loss)$260K$70K$110K-$-80K-$-40K
Total equity$261M$198.1M-$-67.94M$39.3M$61.6M
Total investments$187.3M$182.8M$109.7M$41.7M$64.4M
Total debt$8.25M$6.26M$193.2M$5.85M$4.91M
Net debt-$-67.35M-$-15.68M$177.7M$280K$280K
Cash flow statement
20252024202320222021
Net income-$-59.98M-$-42.26M$22.7M-$-24.25M-$-29M
Depreciation and amortization$320K$260K$200K$330K$330K
Stock-based compensation$10M$6.8M$2.22M$1.93M$1.75M
Change in working capital-$-6.04M$5.33M-$-1.02M-$-1.27M$110K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-870K$1.14M$0.00-$-230K-$-110K
Net cash provided by operating activities-$-55.31M-$-32.84M$19.4M-$-20.12M-$-26.27M
Investments in property, plant and equipment-$-230K-$-510K-$-410K-$-120K-$-170K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-3.71M-$-69.74M-$-65.57M$22.3M-$-64.97M
Common stock issued$112.9M$109M$160K$10K$110K
Common stock repurchased$0.00$0.00-$-30K-$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$112.7M$109M$56.2M-$-1.24M$79.8M
Net change in cash$53.7M$6.42M$9.96M$940K-$-11.39M
Cash at end of period$75.6M$21.9M$15.5M$5.57M$4.63M
Operating cash flow-$-55.31M-$-32.84M$19.4M-$-20.12M-$-26.27M
Capital expenditure-$-230K-$-510K-$-410K-$-120K-$-170K
Free cash flow-$-55.54M-$-33.36M$18.9M-$-20.24M-$-26.43M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Contineum Therapeutics, Inc.

        Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

        CEO
        Carmine N. Stengone
        Employees
        51
        Beta
        0.70

        Explore

        Frequently asked questions

        What is the intrinsic value of Contineum Therapeutics, Inc. (CTNM)?

        InvestorsCraft does not currently publish an intrinsic value for CTNM. How the IC value is calculated.

        Is CTNM undervalued?

        InvestorsCraft does not publish an undervaluation signal for CTNM at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.